Secondary pharmacology publication recognised as ‘Most Impactful Publication of the Year’ by the Safety Pharmacology Society

By Steve Jenkinson, VP Drug Discovery and Safety Assessment, Metrion Biosciences

I’m delighted that the Safety Pharmacology Society have recognised the IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ as the ‘Most Impactful Safety Pharmacology Publication of the Year’ (published in Nature Reviews in Drug Discovery).

I co-chaired this Working Group prior to joining Metrion. As a team, we conducted an extensive survey to highlight similarities and differences in screening strategies and target panels across the pharmaceutical industry and as a result identified a number of opportunities for further optimisation within the secondary pharmacology assessment of novel compounds.

I extend congratulations to IQ Consortium and all other authors.

Read my earlier post about this work.

Brennan, R.J., Jenkinson, S., Brown, A. et al. The state of the art in secondary pharmacology and its impact on the safety of new medicinesNat Rev Drug Discov 23, 525–545 (2024). https://doi.org/10.1038/s41573-024-00942-3

Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram